Philip Vickers joins Shire

pharmafile | October 13, 2010 | Appointment | Research and Development |  Shire, appointment, research and development 

Shire has appointed Philip Vickers as senior VP of research and development for its Human Genetic Therapies (HGT) business.

He will be responsible for leading Shire HGT’s global R&D efforts and establishing the strategic direction of the company’s pipeline.

Philip has more than two decades of pharmaceutical and biotechnology industry experience, and joins Shire from Resolvyx Pharmaceuticals where he was chief scientific officer and president.

Previously, he was US head of research for Boehringer-Ingelheim Pharmaceutical and has also held leadership positions at Pfizer in both the US and UK during a career that began at Merck Frosst in Canada.

“Shire HGT has grown substantially in recent years, and we are pleased to have Phil join us at a crucial time in the growth of the Company,” said Sylvie Gregoire, president of Shire HGT.

“He has the breadth of experience and expertise that will enhance our scientific and business capabilities in forging the long-term vision for the Company, and we will count on him to help us deliver on our promise to patients suffering from rare genetic diseases worldwide.”